Cipla and Glenmark are recalling their drugs in the US because of problems with their manufacturing processes.

In recent news, it has been reported that two pharmaceutical companies, Cipla and Glenmark, have issued recalls for some of their products in the US market. These recalls were prompted by manufacturing issues that were brought to the attention of the US Food and Drug Administration (FDA).

Cipla's subsidiary in New Jersey has recalled a total of 59,244 packs of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution. According to the FDA's Enforcement Report, this particular batch of Cipla products was found to have a "short fill," meaning that the respules contained less volume than they should have. It was also reported that some of the pouches had liquid drops inside, which is not supposed to happen.

The drug being recalled by Cipla is commonly used to control symptoms of lung diseases such as asthma, chronic bronchitis, and emphysema. It is a crucial medication for those who suffer from these conditions, so the recall is being taken very seriously.

In addition to Cipla, Glenmark Pharmaceuticals, a US-based company, has also issued a recall for one of their products. Specifically, 3,264 bottles of Diltiazem Hydrochloride extended-release capsules, which are used to treat high blood pressure, are being recalled due to failed dissolution specifications.

Meanwhile, another pharmaceutical company, Lupin, has also been affected by manufacturing issues. According to the FDA's Enforcement Report, they have recalled 26,352 bottles of Rifampin Capsules, an antibiotic medication, from the US market.

It is concerning to see these recalls happening, as it means that there were errors or defects in the manufacturing process that could potentially impact the effectiveness and safety of these medications. It is important for pharmaceutical companies to maintain strict quality control measures to ensure that their products are safe for consumers to use.

It is also reassuring to see that the FDA is actively monitoring and addressing these issues, as they play a crucial role in ensuring the safety and efficacy of medications in the US market. Let's hope that the necessary steps are taken to rectify these manufacturing issues and that these medications are made available again for those who rely on them for their health.

[This article has been trending online recently and has been generated with AI. Your feed is customized.]